LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2016.
“As we approach the end of the year, our team continues to make progress in advancing the drug candidates in our proprietary pipeline. Concert is well positioned to achieve our goal of having two efficacy studies underway with our proprietary compounds in 2017,” said Roger Tung, PhD, Chief Executive Officer of Concert Pharmaceuticals. “We are excited by the emerging profile of CTP-656, which may provide significant advantages over the current standard of care. We believe these advantages may enable CTP-656 to provide a therapeutic benefit in cystic fibrosis patients with gating mutations. We are also excited to be advancing CTP-543, which has the potential to be the first FDA-approved oral medicine for the treatment of alopecia areata, a significant unmet need.”
“As we approach the end of the year, our team continues to make progress in advancing the drug candidates in our proprietary pipeline. Concert is well positioned to achieve our goal of having two efficacy studies underway with our proprietary compounds in 2017,” said Roger Tung, PhD, Chief Executive Officer of Concert Pharmaceuticals. “We are excited by the emerging profile of CTP-656, which may provide significant advantages over the current standard of care. We believe these advantages may enable CTP-656 to provide a therapeutic benefit in cystic fibrosis patients with gating mutations. We are also excited to be advancing CTP-543, which has the potential to be the first FDA-approved oral medicine for the treatment of alopecia areata, a significant unmet need.”
